SOUTH SAN FRANCISCO, CA and CLEVELAND, OH--(Marketwire - November 16, 2007) - Alios BioPharma, Inc. and Cleveland Clinic today announced that they have entered into an exclusive worldwide license agreement focused on the development of small molecule RNase L activators for the treatment of a broad range of viral diseases such as chronic hepatitis B and hepatitis C, HIV, influenza and others. The technology is also applicable to the treatment of cancer for both solid tumors and hematological malignancies such as leukemia. The agreement grants Alios exclusive worldwide rights to Cleveland Clinic patents, technology and preclinical small molecules relating to RNase L activation which were developed in the laboratory of Robert H. Silverman, Ph.D. Dr. Silverman, Department of Cancer Biology, Cleveland Clinic’s Lerner Research Institute, is a world leader in the field of innate immunity with specific expertise in the RNase L system.
